AI Summary
✦ ClarthaValuation Metrics
Trading 184.9% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.28). Confidence: 50%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
17.40
Current
58.07
Overvalued
36.79
Undervalued
13.60
5Y Average
5.04
Current
16.81
Overvalued
6.50
Undervalued
1.41
5Y Average
12.66
Current
42.24
Overvalued
16.34
Undervalued
3.53
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.4x Undervalued | -24% vs avg | +10.7% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 23.8x Undervalued | -46% vs avg | +17.1% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.5x Fair | +13% vs avg | +0.3% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.5x Premium | +107% vs avg | +123.1% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.3x Undervalued | -17% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.6x Fair | -12% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.0x Fair | -9% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Fair | -12% vs avg | +30.0% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹24 CrMar 2026Latest net profit
₹8.00 CrMar 2026Latest EPS
₹7.11Mar 2026Net margin
35.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
Sales
₹24 Cr
Net Profit
₹8 Cr
EBITDA
₹12 Cr
EPS
₹7.11
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 16 | 18 | 20 | 22 | 24 |
| Expenses | 11 | 13 | 14 | 15 | 16 |
| Operating Profit | 5 | 6 | 6 | 7 | 8 |
| OPM % | 30.33% | 30.79% | 30.89% | 31.57% | 34.98% |
| Other Income | 1 | 1 | 1 | 1 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 6 | 6 | 7 | 8 | 11 |
| Tax % | 23.27% | 24.1% | 24.86% | 26.15% | 24.0% |
| Net Profit | 4 | 5 | 5 | 6 | 8 |
| EPS in Rs | 3.69 | 6.19 | 4.61 | 5.29 | 7.11 |
All values in ₹ Crores unless otherwise stated. Source: Company filings.